Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting
Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers
Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting
Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
- « Previous Page
- 1
- …
- 16
- 17
- 18